Andrew K Sewell Selected Research

preproinsulin

1/2018	Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.
1/2013	Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity.
1/2012	Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.
10/2008	CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew K Sewell Research Topics

Disease

34	Neoplasms (Cancer) 01/2021 - 08/2005
10	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 10/2008
9	Infections 01/2022 - 01/2002
9	Human Influenza (Influenza) 01/2022 - 11/2005
9	Melanoma (Melanoma, Malignant) 01/2019 - 09/2007
6	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 08/2005
3	Communicable Diseases (Infectious Diseases) 01/2019 - 10/2009
2	Leukemia 12/2017 - 12/2005
2	Disease Progression 02/2015 - 12/2012
2	HIV Infections (HIV Infection) 01/2013 - 12/2012
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2008 - 12/2005
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2008 - 12/2005
2	Virus Diseases (Viral Diseases) 03/2007 - 08/2005
2	Persistent Infection 11/2005 - 11/2002
1	Colorectal Neoplasms (Colorectal Cancer) 12/2019
1	Bites and Stings (Sting) 01/2019
1	Tuberculosis (Tuberculoses) 01/2018
1	Ankylosing Spondylitis 01/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2014
1	Osteoporosis 03/2013
1	Acute-Phase Reaction 03/2013
1	Epstein-Barr Virus Infections 11/2010
1	Hyperglycemia 10/2008
1	Necrosis 04/2008
1	Septic Shock (Toxic Shock Syndrome) 12/2007
1	Adenocarcinoma 03/2007
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2005
1	Hematologic Neoplasms (Hematological Malignancy) 12/2005
1	Wilms Tumor (Wilm's Tumor) 12/2005

Drug/Important Bio-Agent (IBA)

33	Peptides (Polypeptides)IBA 01/2022 - 01/2002
22	EpitopesIBA 01/2022 - 01/2002
18	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 08/2005
18	AntigensIBA 01/2019 - 01/2005
12	Proteins (Proteins, Gene)FDA Link 09/2020 - 11/2005
9	HLA Antigens (Human Leukocyte Antigens)IBA 09/2020 - 10/2009
7	HLA-A*02:01 antigenIBA 01/2020 - 12/2005
5	Insulin (Novolin)FDA Link 01/2020 - 10/2008
5	LigandsIBA 01/2020 - 03/2007
5	Indicators and Reagents (Reagents)IBA 01/2018 - 07/2007
4	preproinsulinIBA 01/2018 - 10/2008
4	AutoantigensIBA 01/2018 - 09/2007
3	Glycoproteins (Glycoprotein)IBA 12/2019 - 01/2013
3	HLA-B Antigens (HLA-B)IBA 01/2018 - 12/2012
3	VaccinesIBA 01/2018 - 10/2009
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2019 - 10/2017
2	Leukocyte Immunoglobulin-like Receptor B1IBA 10/2019 - 01/2019
2	HLA-A Antigens (HLA-A)IBA 01/2019 - 01/2018
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2019 - 01/2018
2	Histocompatibility Antigens Class IIIBA 01/2016 - 12/2007
2	Messenger RNA (mRNA)IBA 01/2016 - 12/2005
2	Hemagglutinins (Hemagglutinin)IBA 02/2012 - 01/2012
2	Glucose (Dextrose)FDA LinkGeneric 01/2012 - 10/2008
2	Pharmaceutical PreparationsIBA 04/2008 - 11/2002
1	NucleoproteinsIBA 01/2022
1	Vitamin B Complex (B Vitamins)IBA 01/2020
1	HLA-G Antigens (HLA G)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	AerosolsIBA 01/2018
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2018
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2018
1	Chimeric Antigen ReceptorsIBA 12/2017
1	Peptide FragmentsIBA 07/2017
1	Riboflavin (Vitamin B2)FDA LinkGeneric 01/2016
1	Antigen Receptors (Antigen Receptor)IBA 01/2016
1	Coloring Agents (Dyes)IBA 09/2015
1	Surface Antigens (Surface Antigen)IBA 02/2015
1	Chemotactic FactorsIBA 02/2015
1	Analgesics (Analgesic Drugs)IBA 03/2013
1	AntipyreticsIBA 03/2013
1	Zoledronic Acid (Zometa)FDA Link 03/2013
1	Neutralizing AntibodiesIBA 01/2013
1	HLA-A24 AntigenIBA 01/2013
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2013
1	Immunoglobulin FragmentsIBA 06/2012
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 01/2012
1	HLA-DR1 Antigen (HLA DR1 Antigen)IBA 01/2012
1	LactamsIBA 12/2010
1	SolutionsIBA 12/2010
1	Interleukin-2 (IL2)IBA 04/2008
1	Immunosuppressive Agents (Immunosuppressants)IBA 04/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008
1	CytokinesIBA 04/2008
1	Dasatinib (BMS 354825)FDA Link 04/2008
1	src-Family KinasesIBA 04/2008
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 04/2008
1	Neuraminidase (Sialidase)IBA 03/2008
1	SuperantigensIBA 12/2007
1	MART-1 AntigenIBA 09/2007
1	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2007
1	Mucin-1 (CA 15-3 Antigen)IBA 03/2007
1	Antiviral Agents (Antivirals)IBA 03/2007
1	WT1 ProteinsIBA 12/2005
1	Viral AntigensIBA 11/2005
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 11/2005

Therapy/Procedure

15	Immunotherapy 01/2020 - 12/2005
6	Therapeutics 10/2017 - 10/2008
1	Immunomodulation 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019
1	Highly Active Antiretroviral Therapy (HAART) 01/2013
1	Transplantation 04/2008